Significant Ownership of Peter Evan Harwin
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Peter Evan Harwin focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- West Conshohocken, PA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
1 identity field
Follow Filing Activity
Follow Peter Evan Harwin with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Peter Evan Harwin
Significant Ownership of Peter Evan Harwin
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ORKA | ORUKA THERAPEUTICS, INC. | Common Stock, $0.001 par value per share | 20% | $997,807,627 | +$62,159,599 | 14,572,917 | +6.6% | Harwin Peter Evan | 01 Jul 2026 |
| SYRE | SPYRE THERAPEUTICS, INC. | Common Stock, $0.0001 par value | 10% | $697,101,864 | +$46,907,483 | 9,667,201 | +7.2% | Peter Evan Harwin | 23 Jun 2026 |
| APGE | Apogee Therapeutics, Inc. | Common Stock, $0.00001 par value | 10% | $529,859,960 | +$3,409,683 | 6,808,789 | +0.65% | Peter Evan Harwin | 18 Jun 2026 |
Schedules 13D/G Reported by Peter Evan Harwin:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.